416 related articles for article (PubMed ID: 25532106)
1. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance.
Huynh FC; Jones FE
PLoS One; 2014; 9(12):e114419. PubMed ID: 25532106
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.
Cittelly DM; Das PM; Salvo VA; Fonseca JP; Burow ME; Jones FE
Carcinogenesis; 2010 Dec; 31(12):2049-57. PubMed ID: 20876285
[TBL] [Abstract][Full Text] [Related]
3. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.
Mitra D; Brumlik MJ; Okamgba SU; Zhu Y; Duplessis TT; Parvani JG; Lesko SM; Brogi E; Jones FE
Mol Cancer Ther; 2009 Aug; 8(8):2152-62. PubMed ID: 19671734
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
6. MiRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation.
Ma T; Yang L; Zhang J
Oncol Rep; 2015 Mar; 33(3):1215-20. PubMed ID: 25586125
[TBL] [Abstract][Full Text] [Related]
7. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
[TBL] [Abstract][Full Text] [Related]
8. microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway.
Cui W; Zhang S; Shan C; Zhou L; Zhou Z
FEBS J; 2013 Aug; 280(16):3962-74. PubMed ID: 23786162
[TBL] [Abstract][Full Text] [Related]
9. miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.
Kim Y; Kim H; Park D; Han M; Lee H; Lee YS; Choe J; Kim YM; Jeoung D
Oncotarget; 2016 Mar; 7(9):10297-321. PubMed ID: 26863629
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation.
Suto T; Yokobori T; Yajima R; Morita H; Fujii T; Yamaguchi S; Altan B; Tsutsumi S; Asao T; Kuwano H
Carcinogenesis; 2015 Mar; 36(3):338-45. PubMed ID: 25503932
[TBL] [Abstract][Full Text] [Related]
11. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
13. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
14. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer.
Nagpal N; Ahmad HM; Molparia B; Kulshreshtha R
Carcinogenesis; 2013 Aug; 34(8):1889-99. PubMed ID: 23542418
[TBL] [Abstract][Full Text] [Related]
17. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.
Le XF; Almeida MI; Mao W; Spizzo R; Rossi S; Nicoloso MS; Zhang S; Wu Y; Calin GA; Bast RC
PLoS One; 2012; 7(7):e41170. PubMed ID: 22829924
[TBL] [Abstract][Full Text] [Related]
18. miR-21: A gene of dual regulation in breast cancer.
Zhang C; Liu K; Li T; Fang J; Ding Y; Sun L; Tu T; Jiang X; Du S; Hu J; Zhu W; Chen H; Sun X
Int J Oncol; 2016 Jan; 48(1):161-72. PubMed ID: 26549725
[TBL] [Abstract][Full Text] [Related]
19. miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.
De Cola A; Volpe S; Budani MC; Ferracin M; Lattanzio R; Turdo A; D'Agostino D; Capone E; Stassi G; Todaro M; Di Ilio C; Sala G; Piantelli M; Negrini M; Veronese A; De Laurenzi V
Cell Death Dis; 2015 Jul; 6(7):e1823. PubMed ID: 26181203
[TBL] [Abstract][Full Text] [Related]
20. Calpain4 is required for activation of HER2 in breast cancer cells exposed to trastuzumab and its suppression decreases survival and enhances response.
Kulkarni S; Saju L; Farver C; Tubbs R
Int J Cancer; 2012 Nov; 131(10):2420-32. PubMed ID: 22377768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
